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IPU Submission to the PSI on Draft Guidance for Pharmacists on Safe 
Supply of Non-Prescription Medicinal Products Containing Codeine 
 
1. Introduction 
 The Irish Pharmacy Union (IPU) is the representative and professional body for community 
pharmacists. Its mission is to promote the professional and economic interests of its members. 
Members of the Union aim to provide the best possible professional pharmacy service to all 
members of the public. They are committed to delivering a quality, accessible, personal and 
professional service that puts the patient first and has as its primary goal the optimisation of the 
health and well-being of society. Pharmacists are accountable for their professional conduct and 
strive to maintain the confidence and respect of their patients, customers, the State and other 
professionals in the healthcare field.  
 
 The Union welcomes the opportunity to make a submission to the Pharmaceutical Society of 
Ireland (PSI) on its draft guidance for pharmacists on the safe supply of non-prescription medicinal 
products containing codeine.  
 
2. Pharmacy Policy on Codeine Supply 
The Union agrees that a pharmacy policy addressing the supply of medicines containing codeine 
should be in place. Over the past few years, the IPU has produced a number of Medicines Sales 
Protocols, designed to assist pharmacists and their staff in the appropriate sales of non-prescription 
medicines to the public. Indeed, in early December 2009, the IPU and the Irish Pharmaceutical 
Healthcare Association (IPHA) jointly produced a protocol to assist pharmacists in the sale of 
medicines containing codeine. This protocol was sent to all members of the Union and can be 
downloaded from the IPU website. A copy of the protocol is attached to this submission and the 
PSI is welcome to send it to all pharmacists on the PSI register.   
 
3. Storage of Codeine Medicines 
The Union agrees with the draft guidance that any medicinal product containing codeine must not 
be accessible to the public for self selection and that codeine medicines must be stored in an area of 
the retail pharmacy business where patients cannot self-select the product. The Union believes that 
this area would be behind the counter. This would ensure that all sales of codeine medicines would 
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be under the supervision of the pharmacist, as recommended by the IPU/IPHA Codeine Sales 
Protocol. This is also in line with the guidelines from the Royal Pharmaceutical Society of Great 
Britain (RPSGB), following their consultation in March 2007, in which they highlighted that 
‘restrictions should not preclude methods of display which allow patients to better view pharmacy 
medicines’. It is not practical to store codeine medicines in the dispensary. It is equally important 
that they should be placed in the patient environment, i.e. behind the counter, to facilitate patient 
choice, supported by the advice and supervision of the pharmacist, according to the Codeine Sales 
Protocol.     
 
4. Supply of Codeine Medicines 
 The Union agrees with the draft guidance that the appropriateness for the supply of codeine 
medicines should be determined before each sale and that the duration of treatment should be no 
longer than 3 days. The IPU spearheaded a public awareness initiative, in conjunction with other 
organisations, in August 2007 highlighting the safe use of pain relievers and the problems 
associated with their overuse or abuse. In particular, people were advised to speak to their 
pharmacist on the appropriate use of codeine. The campaign recommended that people always 
follow the instructions which accompany the medicines and not use them for longer than stated on 
the pack, unless advised to do so by their doctor. The campaign highlighted that taking medicines 
which contain codeine for longer than instructed or misusing them can lead to physical and 
psychological dependence. The leaflets distributed during the campaign gave information on how 
and when to use products containing paracetamol, aspirin, ibuprofen and codeine. Posters in the 
pharmacy encouraged people to ask their pharmacist about pain relief. Pharmacists were provided 
with a Medicines Sales Protocol to use for all OTC sales. Local pharmacists around the country 
gave local media interviews. The Union would welcome the opportunity to run such a campaign 
again in association with the PSI.  
 
5. Suspected abuse and/or misuse 
The Union supports the proposal that patients should be facilitated in accessing services which will 
assist in the management of codeine addiction. Indeed, in September 2005, the IPU, in partnership 
with the Health Promotion Unit of the Department of Health and Children, ran a Drugs Awareness 
Campaign. Posters in pharmacies encouraged patients to ask their pharmacist about drugs misuse 
and abuse and leaflets gave details of how to access services. The Union would welcome the 
opportunity to run such a campaign again in association with the PSI. 
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The Union does not believe that an audit or monitor of the sale and supply of codeine medicines is 
necessary as, if pharmacists comply with the Codeine Sales Protocol, any issues of abuse/misuse 
will be addressed.  
 
6. Pharmacovigilance 
The Union regularly reminds members to ensure that any suspected adverse reactions should be 
reported to the Irish Medicines Board via their online reporting system and will continue to do so. 
 
7. Advertising of Codeine Medicines  
The Union agrees that advertising of codeine medicines should be prohibited.  
 
8. Conclusion 
 In conclusion, the Union welcomes the intent of the draft guidance from the PSI on the safe supply 
of non-prescription medicinal products containing codeine. The Union accepts that it is desirable 
that medicines containing codeine should not be available for self selection by the public. However, 
it is not necessary to locate the medicines in the dispensary in order to achieve the objectives of the 
guidance nor is it practical from a pharmacist’s perspective in relation to the efficient workflow in a 
pharmacy or from the patient’s perspective in relation to choice of medicines. The Union looks 
forward to working with the PSI on the production of final guidance to incorporate the issues 
addressed in this submission.  
 
 The Union is available to meet with the PSI to discuss the issues raised above or indeed any other 
relevant issues.  
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PROTOCOL FOR THE SALE OF CODEINE-CONTAINING MEDICINES 
 
This protocol is in line with the requirements of the Pharmacy Act 2007 (20 of 2007), Section 2 of the Misuse of 
Drugs Act 1977 (12 of 1977), Medicinal Products (Control of Advertising) Regulations 2007 (541 of 2007). 
 
Sale and Supply 
 THE SALE OF CODEINE-CONTAINING PRODUCTS MUST BE UNDER THE SUPERVISION OF THE 
PHARMACIST 
 The customer should be interviewed to ascertain if a codeine-containing product is suitable for the condition 
they are seeking treatment 
 
Precautions & Warnings 
 OTC codeine-containing analgesics are for short term use only and should not be taken for longer than 3 
days, unless advised by a doctor 
 Prolonged regular use, except under medical supervision, may lead to physical and psychological 
dependence (addiction) 
 Pharmacists should advise the customer that it is important to follow the dosage instructions on pack and 
not to exceed the stated dose 
 Codeine-containing products should not be taken while breast-feeding unless under the supervision of a 
doctor 
 
Undesirable effects 
 Frequent use of pain-relievers for persistent headaches may make them worse. If you believe that a 
customer may be suffering from Medicine Overuse Headache, offer advice and information leaflets. If it 
persists, recommend they see a doctor. 
 Codeine can cause constipation, nausea, dizziness and drowsiness according to dosage and individual 
susceptibility 
 
Identifying potential for misuse or abuse 
 Frequent request for the same product by the same person 
 Unusual requests from new customers in times of short supply 
 Customer’s behaviour and/or state 
 Customer refusal to purchase an alternative product 
 Irritation by customer about pharmacy staff intervention 
 Customer wants to purchase large quantities of a product 
 Customer gives the excuse that they are buying the product for someone else 
 Product asked for by name or customer has a detailed knowledge of the product 
 Headache present for more than 15 days per month 
 
What to do if Abuse / Misuse is Suspected 
 Politely but firmly inform the patient that you cannot recommend any codeine-containing medicine for them 
and suggest they talk to their doctor. 
 If you suspect that the customer is abusing codeine containing products, alert other pharmacies in the area, 
explaining your observations including a description of the person. 
 Be prepared to offer advice to customers and have useful numbers and information leaflets to hand 
 Offer alternative products,  treatments or advice to people seeking codeine-containing products, where you 
believe a codeine-containing product to be inappropriate 
  
 
